{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:23:54Z","timestamp":1791235434033,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003506","name":"Helse- og Omsorgsdepartementet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003506","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012446","name":"Akershus University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012446","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40259-020-00438-7","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T14:03:57Z","timestamp":1600869837000},"page":"681-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3693-7706","authenticated-orcid":false,"given":"Kristin K.","family":"J\u00f8rgensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guro L.","family":"Goll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Bolstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge C.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Asak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid P.","family":"Berset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid M.","family":"Blomgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Dvergsnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Florholmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein O.","family":"Frigstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magne","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Hagfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Huppertz-Hauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A.","family":"Haavardsholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf A.","family":"Klaasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Moum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir","family":"Noraberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Presteg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Rydning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv","family":"Sagatun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine A.","family":"Seeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roald","family":"Torp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M.","family":"Ystr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut E. A.","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Kvien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-2914","authenticated-orcid":false,"given":"J\u00f8rgen","family":"Jahnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"issue":"978","key":"438_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","volume":"83","author":"A Kuek","year":"2007","unstructured":"Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251\u201360.","journal-title":"Postgrad Med J"},{"issue":"1","key":"438_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198\u2013206.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"438_CR3","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"438_CR4","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"42","key":"438_CR5","doi-asserted-by":"publisher","first-page":"9300","DOI":"10.3748\/wjg.v22.i42.9300","volume":"22","author":"U Billmeier","year":"2016","unstructured":"Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300\u201313.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"438_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biologicals.2014.05.005","volume":"42","author":"BG Feagan","year":"2014","unstructured":"Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42(4):177\u201383.","journal-title":"Biologicals"},{"key":"438_CR7","doi-asserted-by":"crossref","unstructured":"Danese S, Gomollon F, Governing B, Operational Board of E. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7(7):586-9.","DOI":"10.1016\/j.crohns.2013.03.011"},{"issue":"12","key":"438_CR8","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","volume":"14","author":"S Ben-Horin","year":"2016","unstructured":"Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14(12):1685\u201396.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"438_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","volume":"10","author":"KB Gecse","year":"2016","unstructured":"Gecse KB, Lovasz BD, Farkas K, Banai J, Bene L, Gasztonyi B, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016;10(2):133\u201340.","journal-title":"J Crohns Colitis."},{"issue":"3","key":"438_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/ibd\/izy264","volume":"25","author":"A Armuzzi","year":"2019","unstructured":"Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, et al. The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the effectiveness and safety across Italy. Inflamm Bowel Dis. 2019;25(3):568\u201379.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"438_CR11","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, Sorensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76(8):1426\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"438_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/apt.13990","volume":"45","author":"Y Komaki","year":"2017","unstructured":"Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(8):1043\u201357.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"438_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.7326\/M18-1512","volume":"170","author":"A Meyer","year":"2019","unstructured":"Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J. Effectiveness and safety of reference infliximab and biosimilar in crohn disease: a French equivalence study. Ann Intern Med. 2019;170(2):99\u2013107.","journal-title":"Ann Intern Med"},{"key":"438_CR14","doi-asserted-by":"crossref","unstructured":"Uhlig T, Goll GL. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford). 2017;56(suppl_4):iv49-iv62.","DOI":"10.1093\/rheumatology\/kex276"},{"issue":"Suppl 1","key":"438_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1586\/17474124.2015.1091308","volume":"9","author":"J Jahnsen","year":"2015","unstructured":"Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):45\u201352.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"1\u20132","key":"438_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000449088","volume":"35","author":"J Jahnsen","year":"2017","unstructured":"Jahnsen J, Kaasen Jorgensen K. Experience with Biosimilar Infliximab (Remsima(R)) in Norway. Dig Dis. 2017;35(1\u20132):83\u201390.","journal-title":"Dig Dis"},{"issue":"2","key":"438_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","volume":"76","author":"W Park","year":"2017","unstructured":"Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Urena S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"438_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"438_CR19","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK Jorgensen","year":"2017","unstructured":"Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304\u201316.","journal-title":"Lancet"},{"issue":"10111","key":"438_CR20","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/S0140-6736(17)32459-5","volume":"390","author":"P Michetti","year":"2017","unstructured":"Michetti P. Efficacy of infliximab biosimilars in patients with Crohn\u2019s disease. Lancet. 2017;390(10111):2435.","journal-title":"Lancet"},{"issue":"10111","key":"438_CR21","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/S0140-6736(17)33047-7","volume":"390","author":"DG Ribaldone","year":"2017","unstructured":"Ribaldone DG, Saracco GM, Astegiano M, Pellicano R. Efficacy of infliximab biosimilars in patients with Crohn\u2019s disease. Lancet. 2017;390(10111):2435\u20136.","journal-title":"Lancet"},{"issue":"10111","key":"438_CR22","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1016\/S0140-6736(17)32463-7","volume":"390","author":"KK Jorgensen","year":"2017","unstructured":"Jorgensen KK, Lundin KE, Olsen IC, Kvien TK, Jahnsen J. Efficacy of infliximab biosimilars in patients with Crohn\u2019s disease - Authors\u2019 reply. Lancet. 2017;390(10111):2436.","journal-title":"Lancet"},{"issue":"1","key":"438_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40259-017-0256-z","volume":"32","author":"RA McKinnon","year":"2018","unstructured":"McKinnon RA, Cook M, Liauw W, Marabani M, Marschner IC, Packer NH, et al. Biosimilarity and Interchangeability: principles and evidence: a systematic review. BioDrugs. 2018;32(1):27\u201352.","journal-title":"BioDrugs."},{"issue":"6","key":"438_CR24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/joim.12880","volume":"285","author":"GL Goll","year":"2019","unstructured":"Goll GL, Jorgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019;285(6):653\u201369.","journal-title":"J Intern Med"},{"issue":"12","key":"438_CR25","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/ibd.22917","volume":"18","author":"G D\u2019Haens","year":"2012","unstructured":"D\u2019Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218\u201324.","journal-title":"Inflamm Bowel Dis"},{"issue":"10182","key":"438_CR26","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","volume":"393","author":"BD Ye","year":"2019","unstructured":"Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699\u2013707.","journal-title":"Lancet"},{"issue":"2","key":"438_CR27","doi-asserted-by":"publisher","first-page":"e00208","DOI":"10.1002\/prp2.208","volume":"4","author":"S Planes","year":"2016","unstructured":"Planes S, Villier C, Mallaret M. The nocebo effect of drugs. Pharmacol Res Perspect. 2016;4(2):e00208.","journal-title":"Pharmacol Res Perspect."},{"issue":"5","key":"438_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00228-018-2418-4","volume":"74","author":"NW Boone","year":"2018","unstructured":"Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018;74(5):655\u201361.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"438_CR29","first-page":"690","volume":"11","author":"V Razanskaite","year":"2017","unstructured":"Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690\u20136.","journal-title":"J Crohns Colitis."},{"issue":"5","key":"438_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","volume":"32","author":"LE Kristensen","year":"2018","unstructured":"Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, et al. Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32(5):397\u2013404.","journal-title":"BioDrugs."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-020-00438-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:17:51Z","timestamp":1632356271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-020-00438-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["438"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00438-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"23 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding provided by Akershus University Hospital (AHUS). This work was supported by the Norwegian Ministry of Health and Care Services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"<i>KKJ<\/i> reports personal fees from Intercept, Norgine, and Celltrion. <i>GLG<\/i> reports personal fees from AbbVie, Biogen, Eli Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, Orion Pharma, Celltrion, and Boehringer Ingelheim. <i>NB<\/i> reports personal fees received from Orion Pharma, Roche, Napp Pharmaceuticals, Pfizer, and Takeda. <i>ICO<\/i> reports grants from the Norwegian Ministry of Health and Care Services during the conduct of the study and personal fees from Pfizer. <i>EAH<\/i> reports grants from AbbVie, Pfizer, UCB, Roche, and MSD. <i>IPB<\/i> reports personal fees from AbbVie, MSD, Takeda, Hospira, and Ferring. <i>KEAL<\/i> reports grants from MSD and personal fees from Takeda, Orion, AbbVie, Pfizer, and MSD. <i>JJ<\/i> reports personal fees from MSD, AbbVie, Celltrion, Orion Pharma, Takeda, Napp Pharm, AstroPharma, Hikma, and Pfizer. <i>TK<\/i> reports grants from the Norwegian Ministry of Health and Care Services during the conduct of the study and personal fees from AbbVie, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus, Janssen, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira\/Pfizer, Roche, Sandoz, and UCB Pharma. <i>SOF<\/i> reports personal fees from Takeda, Pharmacosmos, Tillotts, Janssen, Intercept, and Pfizer. The remaining authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol and consent documents were approved by an independent ethics committee (Regional Committees for Medical and Health Research Ethics South East; reference number 2014\/848), by appropriate institutional review boards, and by the Norwegian Medicines Agency (reference number 14\/07192-11). The study was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. Trial registration numbers: ClinicalTrials.gov NCT-02148640, EudraCT Number: 2014-002056-40.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients received verbal and written information about the study and signed an informed consent form.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The corresponding author (KKJ) together with the statistician (JS) had full access to all the data in the study and had final responsibility for the decision to submit for publication. The study data are available on request from the authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Statistical analyses were done in Stata version 14.1 and R 3.4.4. Key commands used in the statistical analyses are available upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"<i>KKJ<\/i> contributed to study design, oversaw the implementation of the study at all centres, provided support to study personnel at each site during the study, contributed to data interpretation, and drafted and critically revised the manuscript. She took final responsibility for the decision to submit for publication. <i>JJ<\/i> contributed to study conception and design, interpreted data, and drafted and critically revised the manuscript. He has had full access to all the data in the study. <i>TK<\/i> was the principal investigator who conceived and designed the study, interpreted data, and drafted and critically revised the report. He has had full access to all the data in the study. <i>GLG<\/i> contributed to study design, contributed to data interpretation, and drafted and critically revised the manuscript. <i>JS<\/i> and <i>ICO<\/i> were the study statisticians. <i>JS<\/i> performed the analyses, contributed to data interpretation, and drafted and critically revised the manuscript. <i>ICO<\/i> contributed to study conception, helped design the study, led the development of the electronic CRF, and contributed support to all sites during the study. He contributed to data interpretation and drafted and critically revised the manuscript. <i>NB<\/i> helped design the study, facilitated laboratory analyses of infliximab and anti-drug antibodies, developed the assay for anti-drug antibodies, and planned and organised the study biobank. He helped interpret data and critically revised the manuscript. <i>KEAL<\/i> contributed to study conception and design, in particular, contributing to planning and interpretation of the immunogenicity analyses, and critically revised the manuscript. <i>EAH<\/i> contributed to study conception, helped design the study, helped interpret data, and critically revised the manuscript. <i>DJW<\/i> developed the assay for infliximab drug levels, provided reagents for anti-drug antibody analysis, was instrumental in setting up the infrastructure for these analyses, helped interpret data, and critically revised the report. <i>RK<\/i> performed the immunogenicity analyses, helped organise the study biobank, and critically revised the report. <i>\u00d8A<\/i>, <i>IPB<\/i>, <i>IMB<\/i>, <i>KD<\/i>, <i>JF<\/i>, <i>SOF<\/i>, <i>MH<\/i>, <i>GHH<\/i>, <i>BM<\/i>, <i>GN<\/i>, <i>UP<\/i>, <i>JHR<\/i>, <i>LS<\/i>, <i>KAS<\/i>, <i>RT<\/i>, <i>CV<\/i>, and <i>CMY<\/i> were main investigators at each study site, who implemented the study at their site, collected data, and critically revised the report. <i>JH<\/i> was the user representative and contributed to the design of the trial, data collection from a service user perspective, was crucial in distributing study information to relevant patient populations, and critically revised the report. All authors made substantial contributions to the conception or design of the study, the acquisition, analysis or interpretation of the data; commented on drafts of this paper; and approved the final version. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}